Beili Gao

发表

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.

W. Wang, Jianxing He, He-long Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature

Ranran Dai, Wei Tang, Zhiyao Bao, 2021, Cancer drug resistance.

PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

Yuchao Dong, P. Yue, Chenhong Fang, 2021, Frontiers in Immunology.

Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro.

Qingyun Li, H. Wan, Qinyun Ma, 2011, Oncology reports.

Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study

Xiaofei Wang, Zhiyao Bao, Beili Gao, 2022, Translational lung cancer research.

Angiotensin-( 1-7 ) inhibits the migration and invasion of A 549 human lung adenocarcinoma cells through inactivation of the PI 3 K / Akt and MAPK signaling pathways

Qingyun Li, H. Wan, Liu Qingyun, 2011 .

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Ying Cheng, P. Keegan, Baolan Li, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study

T. Xu, Lei Ni, Xiaofei Wang, 2022, Annals of translational medicine.

Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature

Wei Tang, Wei Chen, Zhiyao Bao, 2021, Annals of translational medicine.

Imperatorin Targets MCL-1 to Sensitize CD133+ Lung Cancer Cells to γδ-T Cell-Mediated Cytotoxicity

Yu Yang, C. You, Beili Gao, 2018, Cellular Physiology and Biochemistry.

Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma

Xue Wu, Y. Shao, H. Bao, 2021, Neoplasia.

Genetic polymorphisms of XPD and CDA and lung cancer risk.

Huan-ying Wan, Beili Gao, Yongjie Ding, 2012, Oncology letters.

Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC

Wei Chen, H. Wan, Yun Feng, 2016, Scientific Reports.

Clinical Features of Pulmonary Sparganosis

Q. Y. Li, Yun Feng, Beili Gao, 2015, The American journal of the medical sciences.

Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells.

Zhi-hong Xu, Jun-biao Hang, Jia-An Hu, 2014, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

Wei Li, C. Bai, Wei Li, 2017, Scientific Reports.

Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways.

Qingyun Li, H. Wan, Qinyun Ma, 2011, Oncology reports.

Monitoring antiangiogenesis of bevacizumab in zebrafish

Zijun Qian, Beili Gao, Wenchao Zhang, 2018, Drug design, development and therapy.

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC

Yun Feng, Lei Ni, Zijun Qian, 2023, Open life sciences.

Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.

Xue Wu, Y. Shao, Xiaofei Wang, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

老年晚期非小细胞肺癌患者药物治疗现状和趋势

Beili Gao, Jianping Zhou, 剑平 Jianping 周 ZHOU, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting

B. Han, Yun Feng, Ying Chen, 2014, Scientific Reports.

SDH mutations, as potential predictor of chemotherapy prognosis in small cell lung cancer patients

Yuchao Dong, Jing Liu, Zhiyao Bao, 2023, Discover Oncology.

Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation

Beili Gao, Ran Zeng, 2022, Frontiers in Medicine.

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

W. Liang, Chuanhao Tang, Jin-liang Wang, 2023, Journal of the National Cancer Center.

Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.

Ying Cheng, He-long Zhang, Cheng Huang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib

W. Gong, Keqiang Chen, Ji Ming Wang, 2017, Oncotarget.